Duality Biotherapeutics, Inc. (HKG:9606)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
305.00
+13.80 (4.74%)
Mar 6, 2026, 2:45 PM HKT
68.51%
Market Cap 26.25B
Revenue (ttm) 2.38B
Net Income (ttm) -3.10B
Shares Out 90.14M
EPS (ttm) -124.82
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 811,050
Average Volume 610,446
Open 291.20
Previous Close 291.20
Day's Range 281.20 - 315.80
52-Week Range 165.50 - 563.50
Beta n/a
RSI 35.39
Earnings Date Apr 2, 2026

About Duality Biotherapeutics

Duality Biotherapeutics, Inc., a clinical-stage biotech company, discovers and develops antibody-drug conjugate (ADC) therapeutics to treat cancer, autoimmune diseases, and others. The company provides DB-1303/BNT323, a HER2 ADC candidate targeting cancers, including endometrial cancer1 and breast cancer2; DB-1311/BNT324, a B7-H3 ADC candidate targeting cancers, such as small-cell lung cancer3, castration-resistant prostate cancer4, esophageal squamous cell carcinoma5, and head and neck squamous cell carcinoma; and other clinical-stage ADCs. It... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2019
Employees 191
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 9606
Full Company Profile

Financial Performance

Financial numbers in CNY Financial Statements

News

There is no news available yet.